about
Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic proteinInhibition of IkappaB kinase by vaccinia virus virulence factor B14Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infectionVaccinia Virus Proteins A52 and B14 Share a Bcl-2–Like Fold but Have Evolved to Inhibit NF-κB rather than ApoptosisTargeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virusPrediction of a novel RNA binding domain in crocodilepox Zimbabwe Gene 157.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus.Novel host-related virulence factors are encoded by squirrelpox virus, the main causative agent of epidemic disease in red squirrels in the UK.Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.Identification of DNA-damage DNA-binding protein 1 as a conditional essential factor for cytomegalovirus replication in interferon-γ-stimulated cells.Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.M135R is a novel cell surface virulence factor of myxoma virusImmune modulation in primary vaccinia virus zoonotic human infectionsPathogeneses of respiratory infections with virulent and attenuated vaccinia viruses.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity.The infectious bursal disease virus RNA-binding VP3 polypeptide inhibits PKR-mediated apoptosisThe 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8.Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccineUnderstanding orthopoxvirus interference with host immune responses to inform novel vaccine design.Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environmentVaccinia virus F1L protein promotes virulence by inhibiting inflammasome activationCowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection.Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells.Dose-dependent lymphocyte apoptosis following respiratory infection with Vaccinia virusPoxvirus host range protein CP77 contains an F-box-like domain that is necessary to suppress NF-kappaB activation by tumor necrosis factor alpha but is independent of its host range function.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.How vaccinia virus has evolved to subvert the host immune response.Viral interference with innate immunity by preventing NF-κB activity.TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry.Vaccinia virus replication is not affected by APOBEC3 family members.Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins.Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection.Vaccinia virus gene F3L encodes an intracellular protein that affects the innate immune response.
P2860
Q24305049-708D6C67-453F-42CA-84C5-87BF1CC3DD89Q24312867-864E6006-1399-4051-B507-CADDF395BF13Q27321985-0D7D89DC-5B6F-47DF-B8DE-174DC8759DC8Q27651621-85F274C2-423D-4A71-8859-D79AF476AC52Q28755816-92A9CA4B-1CC9-4BB8-93F9-2A8926A1BB35Q30416801-76E52198-CB49-44CF-A27B-E5D956F886CFQ33320536-774D187C-2DDD-418F-9341-5EADB7609952Q33373339-82939B6E-7B5F-46D2-A238-5601FFA84332Q33447166-8277F0E4-1EF4-4729-B29C-230E0BABC396Q33725157-57B4148F-7A86-4184-8A9F-E4309FEFFCA4Q33830482-4709CD7E-ACD4-49E4-989F-422AB21A341CQ33910501-854993A5-B3BA-4F97-B9FA-551622B70D77Q33941023-73BCBBAC-0144-4424-A23B-1772950C1E09Q34190609-5FB5759B-2602-4322-93DD-B9053FF9CDCAQ34714569-826C8E27-232D-4DDD-92EB-5428F584345CQ35634308-2D01C566-FDBD-4510-A9C3-07B5871F0EF1Q35645804-4DA0477B-C3BA-448F-B85C-8854DEC33C8EQ35663339-5066F060-4504-4368-BC45-D9281F4CD137Q35947683-30C1B36D-4D69-4F4B-BCF6-3E72E1BAE33CQ36004599-2024AA8A-61A0-46A6-9FA3-93BF930266D4Q36306125-B7CF3B92-8608-4FA7-AECD-431DBB18354AQ36315214-8E54B714-0F5D-41AF-A43F-6B0F8EDAD402Q36484748-F9417CB5-A188-448E-A305-5D96C82D166DQ36728801-1363591C-17E7-453D-8745-4D5CC441529DQ36766169-B318BE13-F6F7-442A-8239-5E0889DFDB07Q36835632-1E6C2817-7300-4E38-B511-0369CDD73094Q36961137-AA47A6BD-C197-4805-8CE7-5699C2805D40Q37011156-82AAC172-509D-4E5C-BCC3-1080CC06BC1CQ37087506-50732BFF-19ED-447C-B1D6-83503A58FCCAQ37157179-BDE32C60-9E68-4812-9DA7-F1F9FAEADC57Q37564490-400384DB-A803-4631-A4CD-F687049BFA99Q37855047-C86B9AA9-E877-4B34-BBA7-9A29B31B1269Q37952350-5181B250-BF39-4346-9C47-844DB5FADA10Q38854837-375808B0-D656-4291-9613-B5E8FA4750DFQ39070584-DF02B3B9-7590-4E4C-BD43-5C61D789CFD9Q39175316-D684EF8A-C961-4609-9393-88D21DE574F9Q39753158-FDDE1DEB-D0FA-46F4-B7A0-0059B908382EQ39758342-37730F9D-2500-45E2-A748-4E0AE80ED6B4Q40026054-02A0B938-B90A-412A-A3F2-22174FD593F3Q40122897-0019B086-8973-41A7-A56A-445FDB8C359B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Evasion of innate immunity by vaccinia virus.
@ast
Evasion of innate immunity by vaccinia virus.
@en
type
label
Evasion of innate immunity by vaccinia virus.
@ast
Evasion of innate immunity by vaccinia virus.
@en
prefLabel
Evasion of innate immunity by vaccinia virus.
@ast
Evasion of innate immunity by vaccinia virus.
@en
P2860
P1433
P1476
Evasion of innate immunity by vaccinia virus.
@en
P2093
P2860
P304
P356
10.1017/S0031182005008127
P478
P577
2005-01-01T00:00:00Z